Literature DB >> 33389659

CXCR4 expression by mesenchymal stromal cells is lost after use of enzymatic dissociation agents, but preserved by use of non-enzymatic methods.

Burcu Pervin1,2, Gözde Aydın1,2, Trudi Visser2, Duygu Uçkan-Çetinkaya1,2,3, Fatima S F Aerts-Kaya4,5.   

Abstract

In recent years, multipotent mesenchymal stromal cells (MSCs) have demonstrated tremendous potential for use in regenerative medicine. CXCR4, the receptor for CXCL12, is highly expressed by bone marrow (BM) MSCs and the CXCR4/CXCL12 axis has been shown to be important for migration and homing of BM-MSCs. Typically, MSCs used for clinical applications are collected after culture expansion using enzymatic methods, such as trypsin. Here, we compared different commercially available enzymatic and non-enzymatic methods for collection and dissociation of MSCs from culture plastics and their effects on CXCR4 expression by MSCs. We found that whereas non-enzymatic dissociation buffers and methods maintained CXCR4 expression, all tested enzymatic dissociation solutions dramatically decreased expression of CXCR4. We, therefore, strongly recommend the use of non-enzymatic dissociation methods, followed by filtration through a cell strainer to obtain single cell suspensions, in order to preserve maximal CXCR4 expression and optimal homing of cells.

Entities:  

Keywords:  CXCR4; Enzymatic dissociation; Mesenchymal stromal cells; Trypsin

Year:  2021        PMID: 33389659     DOI: 10.1007/s12185-020-03043-0

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  18 in total

1.  Defining the risks of mesenchymal stromal cell therapy.

Authors:  Darwin J Prockop; Malcolm Brenner; Willem E Fibbe; Edwin Horwitz; Katarina Le Blanc; Donald G Phinney; Paul J Simmons; Luc Sensebe; Armand Keating
Journal:  Cytotherapy       Date:  2010-09       Impact factor: 5.414

2.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.

Authors:  M Dominici; K Le Blanc; I Mueller; I Slaper-Cortenbach; Fc Marini; Ds Krause; Rj Deans; A Keating; Dj Prockop; Em Horwitz
Journal:  Cytotherapy       Date:  2006       Impact factor: 5.414

Review 3.  Mesenchymal stem cell: keystone of the hematopoietic stem cell niche and a stepping-stone for regenerative medicine.

Authors:  Paul S Frenette; Sandra Pinho; Daniel Lucas; Christoph Scheiermann
Journal:  Annu Rev Immunol       Date:  2013-01-03       Impact factor: 28.527

4.  SDF-1/CXCR4 axis modulates bone marrow mesenchymal stem cell apoptosis, migration and cytokine secretion.

Authors:  Xiaolei Liu; Biyan Duan; Zhaokang Cheng; Xiaohua Jia; Lina Mao; Hao Fu; Yongzhe Che; Lailiang Ou; Lin Liu; Deling Kong
Journal:  Protein Cell       Date:  2011-11-06       Impact factor: 14.870

Review 5.  The SDF-1/CXCR4 axis in stem cell preconditioning.

Authors:  Chiara Cencioni; Maurizio C Capogrossi; Monica Napolitano
Journal:  Cardiovasc Res       Date:  2012-03-26       Impact factor: 10.787

Review 6.  Mutual, reciprocal SDF-1/CXCR4 interactions between hematopoietic and bone marrow stromal cells regulate human stem cell migration and development in NOD/SCID chimeric mice.

Authors:  Ayelet Dar; Orit Kollet; Tsvee Lapidot
Journal:  Exp Hematol       Date:  2006-08       Impact factor: 3.084

7.  Enhanced functional response to CXCL12/SDF-1 through retroviral overexpression of CXCR4 on M07e cells: implications for hematopoietic stem cell transplantation.

Authors:  Nehal K Porecha; Kyle English; Giao Hangoc; Hal E Broxmeyer; Kent W Christopherson
Journal:  Stem Cells Dev       Date:  2006-06       Impact factor: 3.272

8.  CXCL12/CXCR4 signaling and other recruitment and homing pathways in fracture repair.

Authors:  Clare Yellowley
Journal:  Bonekey Rep       Date:  2013-03-13

9.  Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study.

Authors:  Katarina Le Blanc; Francesco Frassoni; Lynne Ball; Franco Locatelli; Helene Roelofs; Ian Lewis; Edoardo Lanino; Berit Sundberg; Maria Ester Bernardo; Mats Remberger; Giorgio Dini; R Maarten Egeler; Andrea Bacigalupo; Willem Fibbe; Olle Ringdén
Journal:  Lancet       Date:  2008-05-10       Impact factor: 79.321

10.  Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells.

Authors:  K Le Blanc; H Samuelsson; B Gustafsson; M Remberger; B Sundberg; J Arvidson; P Ljungman; H Lönnies; S Nava; O Ringdén
Journal:  Leukemia       Date:  2007-05-31       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.